These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25968154)

  • 21. Mucosal healing with anti-TNF antibodies.
    Chevaux JB; Vavricka SR; Rogler G; Lakatos PL; Schoepfer A; Peyrin-Biroulet L
    Digestion; 2012; 86 Suppl 1():16-22. PubMed ID: 23051722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.
    Hudesman D; Lichtiger S; Sands B
    Inflamm Bowel Dis; 2013 Mar; 19(3):644-9. PubMed ID: 23314243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of inflammatory immunologic disease 2. Anti-cytokine therapies in inflammatory bowel disease.
    Matsumoto T
    Intern Med; 2007; 46(16):1307-9. PubMed ID: 17704612
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [1/2 The anti-TNF alpha drugs].
    Medjoub M; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Oct; (719):59-61. PubMed ID: 18020248
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
    Scott DL; Cope A
    Ann Rheum Dis; 2009 Jun; 68(6):767-9. PubMed ID: 19435722
    [No Abstract]   [Full Text] [Related]  

  • 30. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
    Leung Y; Hanauer SB
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S202-8. PubMed ID: 20117343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D
    BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract]   [Full Text] [Related]  

  • 32. Certolizumab pegol.
    Melmed GY; Targan SR; Yasothan U; Hanicq D; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Aug; 7(8):641-2. PubMed ID: 18670430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 34. [Certolizumab pegol--new possibilities in the treatment of Crohn's disease].
    Lazebnik LB; Kniazev OV
    Eksp Klin Gastroenterol; 2012; (3):100-5. PubMed ID: 22830233
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent developments in the treatment of inflammatory bowel disease.
    Rietdijk ST; D'Haens GR
    J Dig Dis; 2013 Jun; 14(6):282-7. PubMed ID: 23419117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease.
    Cesarini M; Danese S
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1243. PubMed ID: 25303376
    [No Abstract]   [Full Text] [Related]  

  • 37. [Certolizumab pegol].
    Delgado Frías E; Díaz González JF
    Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Authors' response.
    Turner D; Friesen C
    J Pediatr Gastroenterol Nutr; 2013 Oct; 57(4):e25-6. PubMed ID: 23820406
    [No Abstract]   [Full Text] [Related]  

  • 39. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic agents in rheumatology: act II.
    Kavanaugh A
    Clin Exp Rheumatol; 2010; 28(3 Suppl 59):S2-4. PubMed ID: 20576218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.